XBIT News and Press, XBiotech Inc. From 07/06/21

AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.’s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-t...

AUSTIN, Texas, June 30, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today it received $75 million from funds escrowed as part of its December 2019 sale of bermekimab. The True Human™ antibody developed by the company to treat inflammatory disorders, including skin...

XBiotech (XBIT) has enrolled the first patient in its 1-BETTER study to evaluate XB2001 in combination with chemotherapy for treatment of Pancreatic Cancer. Safety and tolerability of the regimen, as well as progression-free survival, overall survival and time-to-treatment-failure will be ass...

AUSTIN, Texas, June 23, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in its 1-BETTER study, a randomized, double-blind, placebo-controlled clinical study to evaluate XB2001 in combination chemotherapy for treatment of Pancreatic Cancer. XBiotech...

AUSTIN, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that it had reached an agreement to supply its new cancer drug XB20-01 to INSERM, and its Federation of Digestive Oncology group, a French organization which supports world-leading innovation for treatin...

XBiotech (XBIT) announces that the FDA has granted permission to commence clinical trials with its novel drug candidate for treating patients with pancreatic cancer. The Phase I/II clinical study will evaluate XBiotech’s new drug candidate, XB2001, when added to the ONIV...

AUSTIN, Texas, April 19, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the FDA has granted permission to commence clinical trials with its novel drug candidate for treating patients with pancreatic cancer. From 1992 to 2018 the death rate from pancreatic cancer stead...

XBiotech is an interesting biotech focused on developing True Human antibodies, i.e. derived from natural human immune responses. The company has been in existence since 2005. Its one major success has been the sale of dermatology treatment bermekimab to Janssen in a $1.3m deal. X...

The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in emergency room patients with mild to moderate symptoms of COVID-19.Following a second planned interim analysis of the trial data, an independent d...

After an analysis against mutant COVID-19 virus found in the U.K., XBiotech ([[XBIT]] +4.6%) says its COVID-19 candidate True Human™ antibody therapy may also be used for treating the new coronavirus strain.XBiotech’s candidate that specifically targets the so-called s...